Management of Cervical Intraepithelial Neoplasia in Pregnant Women
Anticancer Research · 2023
DOI: 10.21873/anticanres.16488 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2023. Verfasst von Frederik A Stuebs und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-European Metropolitan Area of Nuremberg (…. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Uterine Cervical Dysplasia. Die Arbeit wurde bisher 2-mal zitiert (Crossref).
Abstract (Originalsprache)
BACKGROUND/AIM: The aims of the present study were to evaluate the accuracy of colposcopic findings, investigate the way in which untreated cervical intraepithelial neoplasia (CIN) 2/3 develops during pregnancy, and identify factors associated with regression, persistence, or progression rates. PATIENTS AND METHODS: In a tertiary gynecology and obstetrics department, 655 pregnant women were seen for colposcopy. The most common reason for referral was abnormal cytology findings. The follow-up findings were analyzed retrospectively on the basis of colposcopic findings and cytological and histological tests. RESULTS: The rate of accuracy for major colposcopic findings was 89.2%. Among the colposcopic findings considered "suspicious for invasion" were invasive carcinoma in 42.9% and CIN 3 in 57.1%. The persistence of CIN 3 postpartum was 80% and the rate of progression 4.1%. The rate of regression for CIN 3 was 21.9%. For CIN 2, the rate of persistence was 37.5%, with a regression rate of 31.3%. The rate of regression was higher after vaginal delivery in comparison with caesarean section. CONCLUSION: The accuracy rate of colposcopy is comparatively high, at 89.2%. This might be because pregnant women are seen by more experienced examiners in our dysplasia unit. The rate of progression is comparable with that in other studies. Vaginal delivery increases the regression rate. The newborns' birth weight or birth week did not affect the rates of regression or persistence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-European Metropolitan Area of Nuremberg (CCC ER-EMN), Erlangen, Germany; frederik.stuebs@uk-erlangen.de.
- Department of Gynecology and Obstetrics, ANregiomed Ansbach Hospital, Ansbach, Germany.
- Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-European Metropolitan Area of Nuremberg (CCC ER-EMN), Erlangen, Germany.
- Department of Medical Informatics, Biometry and Epidemiology, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany.
- Institute of Pathology, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-European Metropolitan Area of Nuremberg (CCC ER-EMN), Erlangen, Germany.
- Institute of Clinical and Molecular Virology, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-European Metropolitan Area of Nuremberg (CCC ER-EMN), Erlangen, Germany.
ORCID-Profile: Frederik A Stuebs
Zitieren
APA
Stuebs, F. A., Koch, M. C., Dietl, A. K., Schulmeyer, C. E., Behrens, A. S., Seibold, A., Adler, W., Geppert, C., Hartman, A., Knoll, A., Beckmann, M. W., Gass, P., & Mehlhorn, G. (2023). Management of Cervical Intraepithelial Neoplasia in Pregnant Women. Anticancer Research. https://doi.org/10.21873/anticanres.16488
Vancouver
Stuebs FA, Koch MC, Dietl AK, Schulmeyer CE, Behrens AS, Seibold A, et al. Management of Cervical Intraepithelial Neoplasia in Pregnant Women. Anticancer Research. 2023. doi:10.21873/anticanres.16488
BibTeX
@article{Stuebs2023,
author = {Stuebs, Frederik A and Koch, Martin C and Dietl, Anna K and Schulmeyer, Carla E and Behrens, Annika S and Seibold, Anja and Adler, Werner and Geppert, Carol and Hartman, Arndt and Knoll, Antje and Beckmann, Matthias W and Gass, Paul and Mehlhorn, Grit},
title = {Management of Cervical Intraepithelial Neoplasia in Pregnant Women},
journal = {Anticancer Research},
year = {2023},
doi = {10.21873/anticanres.16488}
}
EUVIMED